focus -WSS

focus

author：leisure time 2025-09-03 14:37:58 - browse：22238

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Addressing health care workers' trauma can help fight burnout

focus

WSS

Bird flu surveillance in wastewater gets boost from consortium

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Study finds gene variants tied to breast cancer risk in Black women

UnitedHealth argues against case alleging wrongful AI care denials

FDA poised to publish guidelines for clinical trial diversity

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

knowledge

focus

knowledge

How one medical school became remarkably diverse

Digital health: a case of mistaken identity

Medical leaders decry Supreme Court decision on affirmative action

Biogen joins immunology wave with $1.15 billion acquisition of HI

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A controversial new treatment promises to make little people taller

Continuity nursing helped my family in our darkest PICU moments

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Anesthesiologist group: stop taking Ozempic before surgery

Group behind ProMed defends move to subscription

hotspot

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Scrutiny of post

Reports of telehealth's death have been greatly exaggerated

It costs an awful lot of money to give away a kidney

Late stage cancers on the rise after pandemic delayed screenings

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

focus

knowledge

hotspot

knowledge